If you have not yet titrated beyond the starting dose, it is too early to evaluate effectiveness
Am J Respir Crit Care Med (2001) 163:8406
Nonetheless, two IV studies have been published related to Parkinsons disease, one open-label which found significant improvement and a slowing of the disease, and one randomized and double-blinded which found only mild symptomatic improvement
M., Rodrigues, S., Carvalho, A
WHAT'S CHANGING Zepbound vs Saxenda: 2026 Outlook 2026: Saxenda Losing Market Share As newer GLP-1s like Zepbound and Wegovy show superior efficacy, Saxenda (FDA-approved since 2014) is gradually being replaced on formularies
Brand-name GLP-1 drugs can be expensive without insurance, and coverage is inconsistent